Boehringer agrees to comply with CMS' price negotiations over blockbuster Jardiance
Boehringer Ingelheim said Wednesday that it will take part in the first round of price negotiations with the Centers for Medicare and Medicaid Services for its blockbuster type 2 diabetes drug Jardiance (empagliflozin).
“We are committed to engaging in open and transparent conversations with CMS,” the company said in a written statement to Endpoints News. “We look forward to sharing detailed information with CMS on the value of Jardiance and to reinforce the need to invest in scientific medical innovation for the patients we serve.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.